MicroRNAs as Potential Targets for Therapeutic Intervention With Metastasis of Non-small Cell Lung Cancer
Related Experiment Video
Updated: Jan 28, 2026
A Permanent Window for Investigating Cancer Metastasis to the Lung
Published on: July 1, 2021
Ulrich H Weidle1, Fabian Birzele2, Adam Nopora3
1Roche Innovation Center Munich, Roche Diagnostics GmbH, Penzberg, Germany.
Abstract:
The death toll of non-small cell lung cancer (NSCLC) patients is primarily due to metastases, which are poorly amenable to therapeutic intervention. In this review we focus on miRs associated with metastasis of NSCLC as potential new targets for anti-metastatic therapy. We discuss miRs validated as therapeutic targets by in vitro data, identification of target(s) and pathway(s) and in vivo efficacy data in at least one clinically-relevant metastasis-related model. A few of the discussed miRs correlate with the clinical status of NSCLC patients. Using miRs as therapeutic agents has the advantage that targeting a single miR can potentially interfere with several metastatic pathways. Depending on their mode of action, the corresponding miRs can be up- or down-regulated compared to normal matching tissues. Here, we describe therapeutic approaches for reconstitution therapy and miR inhibition, general principles of anti-metastatic therapy as well as current technical pitfalls.
Insights
MicroRNAs (miRs) show promise as novel therapeutic targets for non-small cell lung cancer (NSCLC) metastasis. Targeting miRs can disrupt multiple metastatic pathways, offering new anti-metastatic treatment strategies.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Metastasis is the primary cause of mortality in non-small cell lung cancer (NSCLC).
- Current therapeutic interventions for NSCLC metastasis are limited.
- MicroRNAs (miRs) are increasingly recognized for their role in cancer progression.
Purpose of the Study:
- To review microRNAs (miRs) associated with non-small cell lung cancer (NSCLC) metastasis.
- To evaluate miRs as potential therapeutic targets for anti-metastatic therapy.
- To discuss current therapeutic approaches and challenges.
Main Methods:
- Literature review focusing on miRs implicated in NSCLC metastasis.
- Analysis of miRs with validated in vitro and in vivo efficacy data.
- Assessment of miRs correlating with clinical NSCLC patient status.
Main Results:
- Several miRs have been identified as potential therapeutic targets for NSCLC metastasis.
- Targeting single miRs can simultaneously affect multiple metastatic pathways.
- Some miRs demonstrate correlation with the clinical status of NSCLC patients.
Conclusions:
- MicroRNAs represent a promising avenue for novel anti-metastatic therapies in NSCLC.
- Therapeutic strategies include miR reconstitution and inhibition.
- Technical challenges in miR-based therapy require further investigation.
Related Concept Videos
01:22MicroRNAs
01:22MicroRNAs
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:58Cell Potential and Free Energy
Thermodynamics is the branch of physics dealing with the relationship between heat and other forms of energy. In an electrochemical cell, chemical energy is converted into electrical energy.
Thus, a link can be predicted between cell potential, free energy change, and the equilibrium constant for the reaction. Cell potential can also be measured as the oxidant or the reducing strength, and similar acid-base strength measures are reflected in equilibrium...
01:03Nursing Interventions I: Taxonomy of Nursing Interventions
A nursing intervention is a treatment or action based on scientific concepts and knowledge from the nursing, behavioral, and physical sciences. Identifying and prioritizing nursing interventions based on the desired outcome...
02:30Metastasis
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...